Division of Arbor Pharmaceuticals Inc.
Latest From NitroMed Inc.
The stock market is theater, a company's public show watched daily by churning audiences of thousands, some first-time punters, some gnarly hecklers. For investors, all corporations are merely players, each with their exits and their entrances. And once a quarter, each company takes a curtain call, acknowledging its owner-audience in a ritualized show of humility and subservience.
Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.
Life was much simpler for biotech investors in the 1990s. When Human Genome Sciences Inc. (HGSI), completed its IPO in December 1993, the company's price almost doubled after the second day of trading – everyone profited including the bankers, company management and even the company's investors. That pattern mimicked, albeit less spectacularly, the tripling of Genentech's stock price at its IPO back in October 1980, an event which led to the first rule of biotechnology investing: "Buy at IPO".
The Endocrinologic and Metabolic Drugs Advisory Committee voted 20-2 in favor of approving the combination of phentermine and topiramate for weight loss during its second review of Vivus’ application.
- Drug Delivery
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Arbor Pharmaceuticals Inc.
- Senior Management
Gerald W Bruce, SVP, Commercial Operations
William BJ Jones, VP, Mktg. & Bus. Dev.
L. Gordon Letts, PhD, CSO & SVP, R&D
- Contact Info
Phone: (781) 266-4000
45 Hayden Rd.
Lexington, MA 02421
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.